 |
|
JAMA-EXPRESS
Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status Trials
Mihai Gheorghiade, MD;
Marvin A. Konstam, MD;
John C. Burnett, Jr, MD;
Liliana Grinfeld, MD;
Aldo P. Maggioni, MD;
Karl Swedberg, MD;
James E. Udelson, MD;
Faiez Zannad, MD;
Thomas Cook, PhD;
John Ouyang, PhD;
Christopher Zimmer, MD;
Cesare Orlandi, MD; for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
JAMA. 2007;297:1332-1343. Published online March 25, 2007 (doi:10.1001/jama.297.12.1332).
Context Heart failure causes more than 1 million US hospitalizations yearly, mostly related to congestion. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in this condition.
Objective To evaluate short-term effects of tolvaptan when added to standard therapy in patients hospitalized with heart failure.
Design, Setting, and Patients Two identical prospective, randomized, double-blind, placebo-controlled trials at 359 sites in North America, South America, and Europe were conducted during the inpatient period of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) between October 7, 2003, and February 3, 2006. A total of 2048 (trial A) and 2085 (trial B) patients hospitalized with heart failure and congestion were studied.
Intervention Patients were randomized to receive either tolvaptan (30 mg/d) or matching placebo, within 48 hours of admission.
Main Outcome Measures Primary end point was a composite of changes in global clinical status based on a visual analog scale and body weight at day 7 or discharge if earlier. Secondary end points included dyspnea (day 1), global clinical status (day 7 or discharge), body weight (days 1 and 7 or discharge), and peripheral edema (day 7 or discharge).
Results Rank sum analysis of the composite primary end point showed greater improvement with tolvaptan vs placebo (trial A, mean [SD], 1.06 [0.43] vs 0.99 [0.44]; and trial B, 1.07 [0.42] vs 0.97 [0.43]; both trials P<.001). Mean (SD) body weight reduction was greater with tolvaptan on day 1 (trial A, 1.71 [1.80] vs 0.99 [1.83] kg; P<.001; and trial B, 1.82 [2.01] vs 0.95 [1.85] kg; P<.001) and day 7 or discharge (trial A, 3.35 [3.27] vs 2.73 [3.34] kg; P<.001; and trial B, 3.77 [3.59] vs 2.79 [3.46] kg; P<.001), whereas improvements in global clinical status were not different between groups. More patients receiving tolvaptan (684 [76.7%] and 678 [72.1%] for trial A and trial B, respectively) vs patients receiving placebo (646 [70.6%] and 597 [65.3%], respectively) reported improvement in dyspnea at day 1 (both trials P<.001). Edema at day 7 or discharge improved significantly with tolvaptan in trial B (P = .02) but did not reach significance in trial A (P = .07). Serious adverse event frequencies were similar between groups, without excess renal failure or hypotension.
Conclusion In patients hospitalized with heart failure, oral tolvaptan in addition to standard therapy including diuretics improved many, though not all, heart failure signs and symptoms, without serious adverse events.
Trial Registration clinicaltrials.gov Identifier: NCT00071331
Author Affiliations: Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill (Dr Gheorghiade); Division of Cardiology, Tufts-New England Medical Center, Boston, Mass (Drs Konstam and Udelson); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn (Dr Burnett); Departments of Biometrics (Dr Ouyang) and Clinical Development (Drs Zimmer and Orlandi), Otsuka Maryland Research Institute, Rockville; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison (Dr Cook); Departmento de Diagnostico y Tratamiento, Servicio de Hemodinamia, Hospital Italiano, Buenos Aires, Argentina (Dr Grinfeld); Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy (Dr Maggioni); Sahlgrenska University Hospital/Östra, Gothenburg, Sweden (Dr Swedberg); and Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigations Cliniques, Nancy, France (Dr Zannad).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
QRS Duration in Patients Hospitalized for Worsening Heart Failure--Reply
, , and
JAMA. ;300():1880-1881.
FULL TEXT
RELATED ARTICLES
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
, , , , , , , , , , , , and
JAMA. ;297():1319-1331.
FULL TEXT
Climbing the Mountain of Acute Decompensated Heart Failure: The EVEREST Trials
JAMA. ;297():1374-1376.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A critical look at acute decompensated heart failure from a nephrologist's perspective
Chan
Nephrol Dial Transplant 2009;24:2024-2026.
FULL TEXT
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial
Blair et al.
Eur Heart J 2009;30:1666-1673.
ABSTRACT
| FULL TEXT
Effects of tolvaptan on dyspnoea relief from the EVEREST trials
Pang et al.
Eur Heart J 2009;0:ehp253v1-ehp253.
ABSTRACT
| FULL TEXT
Are BNP Changes During Hospitalization for Heart Failure a Reliable Surrogate for Predicting the Effects of Therapies on Post-Discharge Mortality?
Gheorghiade and Pang
J Am Coll Cardiol 2009;53:2349-2352.
FULL TEXT
End points for clinical trials in acute heart failure syndromes.
Allen et al.
J Am Coll Cardiol 2009;53:2248-2258.
ABSTRACT
| FULL TEXT
A Case for Water in the Treatment of Polycystic Kidney Disease
Torres et al.
CJASN 2009;4:1140-1150.
ABSTRACT
| FULL TEXT
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study
Voors et al.
Eur Heart J 2009;30:1187-1194.
ABSTRACT
| FULL TEXT
Acute heart failure syndromes.
Gheorghiade and Pang
J Am Coll Cardiol 2009;53:557-573.
ABSTRACT
| FULL TEXT
Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil?
Felker et al.
Circ Heart Fail 2009;2:56-62.
FULL TEXT
Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure: Results From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Program
Blair et al.
J Am Coll Cardiol 2008;52:1640-1648.
ABSTRACT
| FULL TEXT
Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction: An International, Multicenter, Randomized, Placebo-Controlled Trial
Udelson et al.
J Am Coll Cardiol 2008;52:1540-1545.
ABSTRACT
| FULL TEXT
Effects of Novel Vasopressin Receptor Antagonists on Renal Function and Cardiac Hypertrophy in Rats with Experimental Congestive Heart Failure
Bishara et al.
J. Pharmacol. Exp. Ther. 2008;326:414-422.
ABSTRACT
| FULL TEXT
Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart Failure: Prediction of Death at Different Stages of the Disease
Neuhold et al.
J Am Coll Cardiol 2008;52:266-272.
ABSTRACT
| FULL TEXT
Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia
Finley et al.
Circulation 2008;118:410-421.
FULL TEXT
Vasodilator therapy for decompensated heart failure.
Yancy
J Am Coll Cardiol 2008;52:208-210.
FULL TEXT
Role of Vasopressin Antagonists
Torres
CJASN 2008;3:1212-1218.
ABSTRACT
| FULL TEXT
When Is It Appropriate to Use Vasopressin Receptor Antagonists?
Lehrich and Greenberg
J. Am. Soc. Nephrol. 2008;19:1054-1058.
ABSTRACT
| FULL TEXT
Vasopressin-receptor antagonists in heart failure
Schweiger and Zdanowicz
Am J Health Syst Pharm 2008;65:807-817.
ABSTRACT
| FULL TEXT
A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach
Pang et al.
Eur Heart J 2008;29:816-824.
ABSTRACT
| FULL TEXT
Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective
Kazory and Ross
Circulation 2008;117:975-983.
ABSTRACT
| FULL TEXT
Overview of emerging pharmacologic agents for acute heart failure syndromes
De Luca et al.
Eur J Heart Fail 2008;10:201-213.
ABSTRACT
| FULL TEXT
The Year in Heart Failure
Tang and Francis
J Am Coll Cardiol 2007;50:2344-2351.
FULL TEXT
Using Homeostatic Peptides in Decompensated Heart Failure: A Reasonable Paradigm But a Flawed Practice?
Silver and Yancy
J Am Coll Cardiol 2007;50:1841-1843.
FULL TEXT
Highlights of the 56th Annual Scientific Session of the American College of Cardiology, March 24-27, 2007. ACC.07 and i2 Summit Highlights: A Conversation With the Experts.
Tuzcu et al.
J Am Coll Cardiol 2007;50:C2-31.
FULL TEXT
Vasopressin and its antagonists: what are their roles in acute medical care?
Mitchell and Hunter
Br J Anaesth 2007;99:154-158.
FULL TEXT
JournalScan
Lindsay
Heart 2007;93:1008-1010.
FULL TEXT
Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet
Cleland et al.
Eur J Heart Fail 2007;9:740-745.
ABSTRACT
| FULL TEXT
Large Trials of Tolvaptan in Acute Heart Failure
Journal Watch Cardiology 2007;2007:3-3.
FULL TEXT
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
Konstam et al.
JAMA 2007;297:1319-1331.
ABSTRACT
| FULL TEXT
Climbing the Mountain of Acute Decompensated Heart Failure: The EVEREST Trials
Yancy
JAMA 2007;297:1374-1376.
FULL TEXT
|
